Abstract | OBJECTIVES: METHODS: Data from three randomised double blind studies were pooled. The studies included patients with clinical symptoms of AMS and sinus X-ray findings of total opacity, air-fluid levels or mucosal thickening. RESULTS: Pooled analysis of results for 5-day telithromycin revealed overall clinical cure rates of 83.6% (383/458 patients) at post- therapy (days 17-24) and 78.9% (330/418 patients) at late post- therapy (days 31-45) in the per-protocol population. Clinical cure rates at post- therapy were equivalent to those observed with 10-day telithromycin (82.5% vs 81.7%) or comparator treatment (80.9% vs 77.4%). Moreover, clinical cure rates exceeded 80% in subgroups of patients of interest, including those with severe infection and those fulfilling more stringent criteria for bacterial AMS. A satisfactory bacteriological outcome was achieved in 87.6% of patients. The 5-day telithromycin regimen was well tolerated. CONCLUSIONS:
Telithromycin once daily for 5 days offers effective treatment for AMS and is comparable to 10-day courses of standard treatments.
|
Authors | K Roos, G Tellier, M Baz, B Leroy, M Rangaraju |
Journal | The Journal of infection
(J Infect)
Vol. 50
Issue 3
Pg. 210-20
(Apr 2005)
ISSN: 0163-4453 [Print] England |
PMID | 15780415
(Publication Type: Comparative Study, Journal Article, Meta-Analysis)
|
Chemical References |
- Anti-Bacterial Agents
- Ketolides
- Amoxicillin-Potassium Clavulanate Combination
- telithromycin
- Cefuroxime
- cefuroxime axetil
|
Topics |
- Acute Disease
- Adolescent
- Adult
- Aged
- Amoxicillin-Potassium Clavulanate Combination
(therapeutic use)
- Anti-Bacterial Agents
(administration & dosage, adverse effects, therapeutic use)
- Cefuroxime
(analogs & derivatives, therapeutic use)
- Drug Administration Schedule
- Drug Resistance, Bacterial
- Female
- Humans
- Ketolides
(administration & dosage, adverse effects, therapeutic use)
- Male
- Maxillary Sinusitis
(drug therapy, microbiology)
- Middle Aged
|